The groundbreaking rise of Sildenafil presented a considerable chance for investors , but its period has expired , creating a complex landscape. Off-brand versions have appeared in the market , eroding sales and putting a squeeze on profit margins . While established pharmaceutical companies maintain a presence in this sector , the future seems unc